TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1978372

Group type: EXPERIMENTAL
Intervention: Ipsapirone at 7.5 mg t.i.d. for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ipsapirone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 356239

Group type: EXPERIMENTAL
Intervention: Proquazone (900 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg)
Number of subjects: 44
Study: 31722332

Group type: COMPARATOR
Intervention: Polysulfone dialysis membrane
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PMMA dialysis membrane
Number of subjects: 25
Study: 31194916

Group type: EXPERIMENTAL
Intervention: Spaced retrieval using dynamic images (video clips without audio)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spaced retrieval using static images
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spaced retrieval using dynamic images
Number of subjects: 12
Study: 27481207

Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA4-Ig) administered via monthly intravenous infusions for 24 weeks, switched to placebo at 28 weeks, final dose at 52 weeks.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo administered via monthly intravenous infusions for 24 weeks, switched to abatacept at 28 weeks, final dose at 52 weeks.
Number of subjects: 65
Study: 25841032

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled dihydroergotamine (DHE)
Number of subjects: 0
Study: 23630134

Group type: EXPERIMENTAL
Intervention: Healthy brain ageing cognitive training program (psychoeducation and cognitive training)
Number of subjects: 50
Study: 21635791

Group type: EXPERIMENTAL
Intervention: MIRA Dhanusha community groups
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: MIRA Dhanusha sepsis management
Number of subjects: 270
Study: 19147478

Group type: EXPERIMENTAL
Intervention: Telephone follow-up by specialist nurses
Number of subjects: 374

Group type: COMPARATOR
Intervention: Traditional hospital follow-up
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 374
Study: 16855921

Group type: EXPERIMENTAL
Intervention: Nabilone (1/4 - 1 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 30
Study: 12865603

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) pretreatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High-dose heparin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Stroke severity (NIHSS) at baseline
Number of subjects: 300
Study: 10885439

Group type: EXPERIMENTAL
Intervention: UVA irradiation (70% of the individual's predetermined minimal phototoxic dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-irradiation control session
Number of subjects: 8
Study: 8967586

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%, 3 ml (15 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%, 3 ml (22.5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 1457358

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg d-1)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 6746977

Group type: EXPERIMENTAL
Intervention: In-vivo participant modeling
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Imaginal participant modeling
Number of subjects: 26
Study: 31490271

Group type: EXPERIMENTAL
Intervention: Modified sutureless and glue-free method (group 1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional sutures (group 2)
Number of subjects: 73
Study: 30266608

Group type: EXPERIMENTAL
Intervention: Stratified medical therapy (intervention group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 151
Study: 26995777

Group type: EXPERIMENTAL
Intervention: Caudal mobilisation with movement (MWM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caudal self-mobilisation with movement (SMWM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 24264126

Group type: EXPERIMENTAL
Intervention: TmLRP‐TT
Number of subjects: 90

Group type: COMPARATOR
Intervention: PKRP
Number of subjects: 90
Study: 22363761

Group type: EXPERIMENTAL
Intervention: Access to personal health records (PHR) or general health information portals
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Training to access and navigate individualized online accounts and complete study surveys
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Intensive on-study training
Number of subjects: 338
Study: 20660670

Group type: EXPERIMENTAL
Intervention: Caspofungin (CAS) 50 mg/day; day 1, 70 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (LAMB) 3 mg/kg of body weight/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination of CAS and LAMB (CASLAMB)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Caspofungin (CAS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (LAMB)
Number of subjects: 55
Study: 17437745

Group type: EXPERIMENTAL
Intervention: Increased pulmonary pressure
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Right ventricular systolic pressure increase
Number of subjects: 388
Study: 16363196

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg plus 2 g/day chitosan in two divided doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg plus placebo
Number of subjects: 100
Study: 11984689

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 106

Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 106
Study: 11528488

Group type: EXPERIMENTAL
Intervention: HPOHC diet (high in palm oil and high in eggs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LOPOMC diet (no palm oil and moderate in eggs)
Number of subjects: 28
Study: 9389862

Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion
Number of subjects: 49
Study: 7956214

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (9-week on, 1-week off regimen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Desogestrel-containing oral contraceptive (traditional regimen)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (both regimens)
Number of subjects: 30
Study: 3575253

Group type: EXPERIMENTAL
Intervention: Theophylline-sodium-glycinate solution administered orally after a standard breakfast (5.6 mg/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline-sodium-glycinate solution administered orally on an empty stomach (5.6 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of theophylline-sodium-glycinate solution under fasting conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of theophylline-sodium-glycinate solution
Number of subjects: 10
Study: 28749093

Group type: EXPERIMENTAL
Intervention: Low volume saphenous‐obturator block
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Femoral‐obturator block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo block
Number of subjects: 82
Study: 27584814

Group type: EXPERIMENTAL
Intervention: HF10 therapy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Traditional SCS
Number of subjects: 198
Study: 26568428

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4 then 200 mg every 2 weeks (Q2W)
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo (Q2W) during the double-blind phase, then switched to CZP in the open-label phase
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 955
Study: 24015649

Group type: EXPERIMENTAL
Intervention: Advanced percutaneous vertebroplasty
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine percutaneous vertebroplasty
Number of subjects: 28
Study: 20799592

Group type: EXPERIMENTAL
Intervention: silymarin (70 mg x 3/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 19057252

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac arthrodesis using percutaneously inserted fusion cages filled with bone morphogenic protein
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 13
Study: 16806096

Group type: EXPERIMENTAL
Intervention: Atomoxetine (titrated to a maximum dose of 1.8 mg/kg/day) administered once daily for up to 7 weeks
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 318
Study: 12782954

Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole by mouth in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 2 g of metronidazole
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Subset of HIV-infected men with trichomoniasis
Number of subjects: 411

Group type: COMPARATOR
Intervention: HIV-positive control subjects
Number of subjects: 411
Study: 10971246

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Noncoated circuits (Group 1)
Number of subjects: 80
Study: 8780763

Group type: EXPERIMENTAL
Intervention: Warmed local anesthetic solution at 40 degrees C
Number of subjects: 16

Group type: COMPARATOR
Intervention: Room temperature local anesthetic solution
Number of subjects: 16
Study: 1610995

Group type: EXPERIMENTAL
Intervention: Untreated arterial blood pressure during CPB (Group 1, 14 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Phenylephrine to maintain arterial pressure above 70 mmHg (Group 2, 7 patients)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 29970144

Group type: EXPERIMENTAL
Intervention: noisy galvanic vestibular stimulation (nGVS) (0.4 mA; 0.1-640 Hz)
Number of subjects: 32

Group type: COMPARATOR
Intervention: sham stimulation (control)
Number of subjects: 32
Study: 26890554

Group type: EXPERIMENTAL
Intervention: Recorded lullabies
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Taped maternal voice
Number of subjects: 62

Group type: COMPARATOR
Intervention: No standardized acoustic stimulation (control group)
Number of subjects: 62
Study: 24007426

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 130
Study: 22569131

Group type: EXPERIMENTAL
Intervention: Home performance on heating soup
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Home performance on cutting fruit
Number of subjects: 33
Study: 19710251

Group type: EXPERIMENTAL
Intervention: Daily inhaled corticosteroid (ICS) medication adherence
Number of subjects: 92
Study: 18430852

Group type: EXPERIMENTAL
Intervention: (1)H-MR spectroscopy
Number of subjects: 39
Study: 16870741

Group type: EXPERIMENTAL
Intervention: High-field functional magnetic resonance imaging and wide-field retinotopic stimulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cortical surface-based analysis
Number of subjects: 34
Study: 12563673

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha monoclonal antibody
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11289667

Group type: EXPERIMENTAL
Intervention: Enzyme linked immuno assay (ELISA) for detection of 170 kDa lectin antigen in feces
Number of subjects: 170

Group type: COMPARATOR
Intervention: Fecal culture method
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Presence of fecal anti‐lectin IgA antibodies and serum anti‐LC3 IgG antibodies
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Infection with Trichomonas hominis
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Infection with Blastocystis hominis
Number of subjects: 170
Study: 9069480

Group type: EXPERIMENTAL
Intervention: Patient with cerebellar lesion
Number of subjects: 1

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 1
Study: 8422345

Group type: EXPERIMENTAL
Intervention: Fish oil ethyl ester (K‐85, 5.7 g/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of K‐85 and Lovastatin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 14
Study: 3722962

Group type: EXPERIMENTAL
Intervention: Rifampin (RMP) 900 mg once weekly for ten weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen C: daily RMP 600 mg, ethionamide (ETH) 500 mg, and DDS or clofazimine (CLO) 100 mg for six months, followed by six months of daily DDS or CLO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen D: identical to regimen C but comprising daily DDS or CLO plus ETH 500 mg during the second semester
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine (CLO) 100 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: MB-WHO regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens C and D
Number of subjects: 0
Study: 29439005

Group type: EXPERIMENTAL
Intervention: Personalised mobile app intervention for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26889794

Group type: EXPERIMENTAL
Intervention: Active tDCS (n=9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS (n=6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (Active tDCS and Sham tDCS)
Number of subjects: 15
Study: 24269507

Group type: EXPERIMENTAL
Intervention: New DIETs (plant-based dietary approaches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mPOD (standard reduced calorie dietary approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mPOD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New DIETs
Number of subjects: 0
Study: 22987877

Group type: EXPERIMENTAL
Intervention: Liquid human milk fortifier (LHMF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control powder human milk fortifier (HMF)
Number of subjects: 150
Study: 20375190

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for children aged 2-11 months, 20 mg for children aged ≥12 months)
Number of subjects: 2628
Study: 18279034

Group type: EXPERIMENTAL
Intervention: Cognitive training (n = 53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standardized multidimensional care (n = 52)
Number of subjects: 105
Study: 16360995

Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory (NSAIDs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 80
Study: 12610740

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily for 2.5 days
Number of subjects: 9
Study: 10622283

Group type: EXPERIMENTAL
Intervention: 3H-paroxetine binding after one year's treatment with different drugs
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3H-paroxetine binding before treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3H-paroxetine binding after one year's treatment
Number of subjects: 20
Study: 7668493

Group type: EXPERIMENTAL
Intervention: Intravenous fluid administration, analgetics, avoidance of oral fluid or food intake in mild acute pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis in severe acute pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assisted ventilation and renal dialysis in severe acute pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate volume replacement and nutritional support in severe acute pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral nutrition in pancreatitis treatment
Number of subjects: 0
Study: 1719242

Group type: EXPERIMENTAL
Intervention: 2 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Number of subjects: 225

Group type: COMPARATOR
Intervention: 4 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Number of subjects: 225
Study: 7005780

Group type: EXPERIMENTAL
Intervention: High-dose naproxen (1250 mg/day for 5 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose naproxen (500 mg loading dose, then 750 mg/day for 5 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31603732

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using two diode lasers with doses of 35.71 J/cm2 and 27.77 J/cm2, applied daily in contact and perpendicular to the skin.
Number of subjects: 2
Study: 31620980

Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab RP
Number of subjects: 0
Study: 28939066

Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg every 2 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Investigator's choice (IC)
Number of subjects: 34
Study: 25293644

Group type: EXPERIMENTAL
Intervention: Comprehensive continuum of care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23460074

Group type: EXPERIMENTAL
Intervention: MTX plus etanercept
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 459
Study: 20864245

Group type: EXPERIMENTAL
Intervention: Maternal smoking habit
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Parental smoking habits
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Number of smokers in the household
Number of subjects: 3026
Study: 19092007

Group type: EXPERIMENTAL
Intervention: Buechel‐Pappas (BP) implant
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scandinavian Total Ankle Replacement (STAR) implant
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both BP and STAR implants
Number of subjects: 200
Study: 17295587

Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine replacement (TNR)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine replacement (TNR)
Number of subjects: 134

Group type: COMPARATOR
Intervention: 0 mg transdermal nicotine replacement (TNR)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 15023596

Group type: EXPERIMENTAL
Intervention: WELL diet (DASH type diet with weight loss focus)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WELL diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: NHF diet
Number of subjects: 40
Study: 10759625

Group type: EXPERIMENTAL
Intervention: ABT‐229 10 mg b.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABT‐229 5 mg b.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8724443

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1331484

Group type: EXPERIMENTAL
Intervention: Black patients with KPS of 90 or more
Number of subjects: 1565

Group type: COMPARATOR
Intervention: White patients with KPS of 90 or more
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Black patients with KPS of less than 90
Number of subjects: 1565

Group type: COMPARATOR
Intervention: White patients with KPS of less than 90
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Overall survival for Blacks and Whites
Number of subjects: 1565
Study: 3886563

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 27

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 27
Study: 29273692

Group type: EXPERIMENTAL
Intervention: Highly-intensive practice (4 hours daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderately-intensive practice (2 hours daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting period
Number of subjects: 30
Study: 27140929

Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride (4-week trial including 2-week placebo and 2-week treatment)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (2-week period)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (2-week treatment)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline assessment (1-week typical sleep)
Number of subjects: 48
Study: 24705418

Group type: EXPERIMENTAL
Intervention: Cranberry prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: TMP-SMX prophylaxis
Number of subjects: 0
Study: 22153966

Group type: EXPERIMENTAL
Intervention: Post-operative lipid management after CABG
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Diabetic patients post-operative lipid management after CABG
Number of subjects: 440
Study: 20459006

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (operation group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Closed reduction and splintlet fixation or cast application (non-operation group)
Number of subjects: 78
Study: 17921383

Group type: COMPARATOR
Intervention: 25000 IU vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50000 IU vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100000 IU vitamin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 IU vitamin A
Number of subjects: 0
Study: 16251235

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571